Join us for a two-part series as we discuss the
challenges and breakthroughs in immuno-oncology research 

Part 1: Hear from our Agilent Experts!

February 11, 2021

08:00am - 09:30am PT
11:00am - 12:30pm ET
04:00pm - 5:30pm BST

The next generation of immune cell therapies require a new generation of analysis tools. Come to explore our new virtual immunotherapy lab.

A safe, potent, and persistent immune cell product depends on developers mustering the full repertoire of immune cell function; activation, proliferation, cell fate, cytotoxic killing, immunomodulation, and memory - all of which must be accomplished in the ever-changing, suppressive, and toxic tumor microenvironment.

Agilent is dedicated to supporting these next-generation therapies, providing key technologies to enable high-efficiency gene editing and assessment of real-time cell function, phenotype, and fate. Used together, this tool bench provides the capability to measure and control immune cell function, thus enabling translational researchers and developers to achieve the necessary level of therapeutic potency and safety.

Register for our Virtual Roadshow, where we will be joined by Agilent product experts who will showcase relevant product lines and assays, including Seahorse XF technology, xCELLigence RTCA, NovoCyte Flow Cytometry and BioTek Instruments.

Meet our presenters

Welcome & Introduction – How Immuno-oncology is rapidly changing the landscape of cell analysis

Immuno-oncology is the change agent for targeting the cellular nature of the immune system. We will discuss how this has created a new set of demands for cell analysis tools that enable discovery and novel strategies for targeting a collaborative cellular network.

Dr. Ferrick received his PhD from Georgetown University and charts an impressive career from University of California professor, to serial entrepreneur and currently life science industry executive. Author to more than 150 peer reviewed publications, several book chapters and 13 patents, David has commercialized many life science products into new and emerging markets and advanced several drug screening programs from target identification to preclinical testing.

Dr. David Ferrick
Associate VP
Cell Analysis Division, Agilent 

Central Role of Immune Cell Bioenergetic Metabolism in Building Next Generation Cell Therapies

Agilent Seahorse XF technology is the gold standard method to measure cell bioenergetic metabolism in life cells in real time. Bioenergetic metabolic measurements in immune cells can provide insightful information about cell function and modulation of metabolic pathways can be utilized to re-direct cell fate. In this workshop we will discuss how XF Seahorse assays have been successfully applied to address the challenges of cell engineering and manufactory process during the design and development of new immunotherapeutics.

Dr. Natalia Romero is a Senior R&D Scientist at the Cell Analysis Division of Agilent Technologies where she leads the development of new kits and assays to study bioenergetic metabolism and cell function using Seahorse XF technology.

Dr. Natalia Romero
Research & Development Scientist
Cell Analysis Division, Agilent

A Simple and Robust Potency Assay for Engineered Immune Cells

End-point biochemical assays typically utilized to measure the cytotoxic potential of TCRs or CAR-Ts are labor intensive and provide limited data. In contrast, the Agilent xCELLigence RTCA eSight generates more detailed biological information during a T cell cytotoxicity assay without increasing the workload.

Brandon Lamarche received his Ph.D. in chemistry from Ohio State University, where his research focused on the chemistry and enzymology of DNA damage and repair, seeking to understand the ways in which organisms strike a balance between these two opposing processes to maintain their fitness, fuel their evolution, and defend themselves against pathogens.

He subsequently worked as a postdoctoral fellow at the Salk Institute where he studied the biochemistry of DNA double strand break (DSB) repair, with particular emphasis on the type of DSBs generated by cancer chemotherapeutics. He now works as a principal scientist at Agilent Technologies where he focuses on developing real-time cell analysis applications using the xCELLigence platform. Currently, his two primary fields of interest are cancer immunotherapy and infectious diseases.

Dr. Brandon Lamarche
Research & Development Scientist,
Cell Analysis Division, Agilent

Immune Cell-mediated Cytotoxicity Assays using Plated Cells and 3D Cell Cultures

Combining microplate reader detection and automated digital microscopy enables a wide range of immune cell-mediated cytoxicity assays using both conventional in vitro cell culture and 3D cell culturing methods. Data will be presented for ADCC assays using multiple non-radiometric readouts and immune cell-mediated cytotoxicity assays quantified with fluorescence and brightfield microscopy.

Peter Banks is currently the Scientific Director at BioTek Instruments, Inc – now a part of Agilent. His responsibilities include the management of the company’s applications team and providing scientific guidance to the senior management team on new technology and emerging trends impacting life sciences.

Dr. Peter Banks
Scientific Director
BioTek Instruments, Inc.
now a part of Agilent

For Research Use Only. Not for use in diagnostic procedures.

©2021 Agilent Technologies